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Abstract 
Postpartum haemorrhage contributes to 25% of maternal deaths worldwide, rising to 40% in 
Sub-Saharan Africa. Treatment of postpartum haemorrhage—particularly for anaemic 
women—requires timely, quality blood transfusions. There are a number of barriers to the 
provision of transfusion services, especially in low- and middle-income settings where the 
need is the greatest. These include unavailability of blood, unsafe blood, poor uptake of 
labour and delivery care, difficulties getting blood to transfusing facilities, and poor 
documentation of patient information. Examples of innovative and practical solutions to 
overcome these barriers are highlighted.  
Keywords: postpartum hemorrhage, anemia, blood transfusion, innovation, LMICs
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ESTABLISHING THE NEED FOR BLOOD TRANSFUSIONS FOR THE 
TREATMENT OF POSTPARTUM HAEMORRHAGE 
 
USE OF BLOOD IN HIGH-INCOME AND LOW-INCOME SETTINGS 
Blood and blood components have been recognised since 2013 as essential medicines. That 
is, items that are needed to meet the priority health needs of a population (1). The World 
Health Organization recommends that: 
1. There should be a centralised, nationally-coordinated blood transfusion service. 
2. Donations should only come from voluntary, non-remunerated donors from low-risk 
populations. 
3. All donated blood must be tested for transfusion-transmitted infections, blood 
grouping, and compatibility. 
4. Unnecessary transfusions must be reduced whenever possible through the effective 
clinical use of blood and the use of alternatives (2). 
 
There are markedly different uses of blood in higher- and lower-income settings. In high-
income countries, blood transfusions are most commonly used for supportive care in heart 
and transplant surgeries, to treat massive trauma, or for therapeutic use in oncology. In these 
settings, 79% of transfusions are given to people over the age of 60. However, in low- and 
middle-income countries (LMICs), two-thirds of blood transfusions are given to anaemic 
children under the age of five, followed by use in the treatment of maternal complications, 
the most common of which is postpartum haemorrhage (PPH) (3). In Sub-Saharan Africa in 
particular, specific factors place considerable strain on the blood supply, including a high 
prevalence of anaemia, malaria, and poor transfusion medicine infrastructure (4). 
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Overall, a usage rate of 32 units of blood per 1000 persons is reported in high-income 
countries, 12.5 units in upper middle income countries, 5.38 units in lower-middle income 
countries, and 3.41 units in low-income countries (5, 6). These data suggest that there is a 
significant under-utilisation of blood in LMICs (3).  
 
BURDEN OF POSTPARTUM HAEMORRHAGE 
Severe PPH (5–7) (see Chapter XX) is highly likely to require a blood transfusion to manage 
potential complications of blood loss. A review in 2012 found that, worldwide, 10.8% of 
women giving birth experienced PPH, with the highest concentration of these women 
residing in Africa, where 25.7% of women giving birth experienced PPH. Only 2.8% of 
women experienced a blood loss of more than 1000 ml, the highest burden again 
concentrated in the African region, where it impacted 5.1% of women (8). When a woman 
experiences severe PPH and is in need of a blood transfusion, death can occur within two 
hours. Therefore timely access to blood transfusion is of utmost importance (7). 
 
BURDEN OF ANAEMIA 
Globally, an estimated 50% of pregnant women are affected by anaemia (6), the majority of 
whom are found in South Asia and Central and West Africa (9). The prevalence of anaemia 
among pregnant women in low- and middle-income countries ranges from 25% to 65% (10). 
There is a relationship between anaemia and PPH. Women with anaemia are not only more 
likely to have PPH, but they are much more likely to have an adverse clinical outcome from 
even much smaller volumes of blood loss (6). For example, one study in India found that 
35% of pregnant women had moderate-to-severe anaemia. Women with severe anaemia were 
at 9.45 increased odds of experiencing PPH. These odds increased 17-fold for women with 
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moderate-to-severe anaemia who had their labour induced, and 19-fold for those with 
anaemia and infection (11).  
 
Anaemia therefore presents a double burden by increasing both the likelihood and severity of 
PPH that necessitate a blood transfusion. Unfortunately, anaemia and PPH are both 
concentrated are in LMICs where access to timely, quality blood transfusion services is 
limited (9). 
  
THE IMPORTANCE OF COMPREHENSIVE EMERGENCY OBSTETRIC CARE 
FACILITIES 
There are many different mechanical and medical interventions that can be carried out in 
order to manage PPH (see Chapter XX). However, where these fail, a blood transfusion may 
become necessary to save a woman’s life (13–15). As part of this life-saving package of care, 
emergency obstetric care is a key strategy for reducing maternal mortality (16). Blood 
transfusions, however, are a key requirement for comprehensive, but not basic, facilities that 
offer emergency obstetric care (Table 1).  
 
Table 1. Basic emergency and comprehensive emergency obstetric care components (17) 
Basic emergency obstetric care Comprehensive emergency obstetric care 
Intravenous or intramuscular antibiotics All components of basic emergency 
obstetric care 
Intravenous or intramuscular uterotonic 
drugs for the active management of the third 
stage of labour and prevention of PPH 
Provision of caesarean section 
Intravenous or intramuscular 
anticonvulsants for the management of pre-
eclampsia/eclampsia 
Provision of blood transfusions  
Manual removal of the placenta  
Manual removal of retained products of 
conception 
 
Assisted vaginal delivery (e.g. vacuum  
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extraction or forceps delivery) 
Resuscitation of newborn baby using a bag 
and mask 
 
 
The most frequent use of blood for obstetric complications is for the treatment of PPH but 
transfusions are also needed to prevent deaths from antenatal haemorrhage and  
complications of abortion, ectopic pregnancy, and ruptured uterus (17). 
 
Comprehensive emergency obstetric care is typically offered at district or regional hospitals 
though not all facilities are able to provide blood transfusions. (Table 2) (18). 
 
Table 2. Examples of distribution of transfusing facilities between hospitals and non-hospitals 
in a selection of low- and middle-income countries (18) 
Country Percentage hospitals 
providing transfusions 
Percentage non-hospitals 
providing transfusions 
Benin 81% 0% 
Kenya 75% 11% 
Mali 33% 12% 
Mozambique 100% 29% 
Uganda 97% 1% 
Bangladesh 97% 0% 
India 9–56% 0% 
Nepal 31% 1% 
 
The reasons for this include poor infrastructure, inability to adhere to regulations, lack of staff 
capacity, shortages of reagents and screening supplies, and inadequate laboratory support 
(18). 
 
These findings highlight the need for more equitable access to timely transfusion and for 
effective referral systems (7). Expansion of comprehensive emergency obstetric care capacity 
across settings has been recognised as important. In particular, improving the ability and 
supply of specialists, provision of caesarean kits, and provision of blood transfusion services 
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that are free to the user have been some priority areas of improvement identified by 
practitioners (19). 
 
THE IMPACT OF BLOOD TRANSFUSION ON MORTALITY DUE TO 
POSTPARTUM HAEMORRHAGE 
There has been a slow decline in maternal mortality ratios, and globally, 99% of maternal 
deaths are concentrated in LMICs. Nearly two-thirds of these deaths occur in Sub-Saharan 
Africa alone, or about 201,000 maternal deaths per year (20). PPH is the most common cause 
of maternal mortality worldwide, contributing to 25% of maternal deaths, and up to 40% of 
maternal deaths in Sub-Saharan Africa (21). Globally, 68% of maternal deaths occur in the 
postpartum period (22). 
 
Lack of blood for transfusion is responsible for unnecessary deaths from PPH. Studies of 
maternal haemorrhage deaths in Sub-Saharan Africa found that 26% (16–72%) of deaths 
were due to a lack of blood (7). A confidential enquiry into maternal deaths  in South Africa 
found that for 35% of maternal deaths, problems including transport between facilities, lack 
of access to intensive care, lack of blood, and unavailability of staff were implicated (23). In 
another study from Uganda, lack of blood transfusions was a key missing signal function 
across facilities, increasing the odds of maternal death 13.7-fold (24). Globally, up to 150,000 
maternal deaths could be prevented through access to safe blood (25). 
 
While the exact need for blood for PPH in Sub-Saharan Africa has not been calculated, a 
rough estimation based on crude birth rates, current population levels, and the prevalence of 
anaemia and severe PPH, suggests that 1,850,000–9,000,000 blood transfusions might 
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reasonably be expected for the management of PPH alone (4). This value may well exceed 
the total amount of blood (i.e. 5.6 million units) donated annually in Sub-Saharan Africa (3).  
 
CHALLENGES AND POTENTIAL SOLUTIONS FOR ENSURING EFFECTIVE 
BLOOD TRANSFUSION SERVICES FOR POSTPARTUM HAEMORRHAGE 
In LMICs in particular, women do not consistently receive the blood transfusions they need, 
when they need them, for PPH. There are a number of reasons for this lack of timely 
provision of safe blood, including a lack of reagents and transfusing supplies, lack of trained 
staff, high background prevalence of transfusion-transmitted infections and screening tests 
with insufficient sensitivity, inadequate blood bank storage facilities, transportation and 
referral barriers, high costs of blood, and poor implementation of existing national blood 
policies (7, 26-29).  
 
BLOOD DONATION 
The rate of donation of blood is 33.1/1000 people in high-income settings, 11.7 in middle-
income settings, and 4.6 in low-income settings. Overall, despite having 48% of the world’s 
population, donors from LMICs contribute only 24% of the global blood supply (3). 
Globally, people’s perspective about blood donation are different. In LMICs, there tend to be 
misconceptions about the purpose and safety of blood donation, but high levels of pro-social 
motivation (30, 31). As a result of cultural barriers, misconceptions, high rates of donor 
ineligibility, and poor donation infrastructure, sufficient numbers of blood donations are 
chronically lacking, producing serious inequalities in the availability of blood.  
 
In many LMICs, transfusion services are hospital-led. If a woman experiences PPH and 
needs blood, it is often the responsibility of the family to find a “replacement donor” to 
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replace the blood used to treat the woman, sometimes having to pay the donor. These 
replacement donations will be screened by the hospital for infections, and undergo grouping, 
and compatibility testing. Unfortunately, this system prone to delays, as well as 
inconvenience and potential hardship for families (32). The alternative to the hospital-based 
model is the centralised model, in which blood transfusion services are centralised, typically 
at the national level. Here, blood donation is organised through recruitment campaigns and 
targets voluntary, non-remunerated donors. Ideally, these donors become repeat donors, who 
have the best safety profile among blood donors, due to regular testing (21, 33). A centralised 
system benefits from quality assurance systems and more sophisticated tests than are 
available in hospitals (29). While the centralised model had its advantages, and is preferable 
in well-resourced contexts, it is very difficult to operationalise within LMICs. In these 
settings, the cost of a centralised blood service is often prohibitive, due to the added costs of 
donor recruitment campaigns, dedicated collection teams, vehicles, cold chain maintenance, 
quality assurance mechanisms, and regular distribution of blood to distant facilities (29, 32, 
34). A unit of blood from the centralised model may cost 4–8 times as much as a unit of 
blood from a hospital-based model (32). 
 
In practice, many LMIC countries have adopted an approach that combines the centralised 
model’s lower-risk donors and quality assurance systems, while supporting hospitals to 
collect and maintain their own blood stores (29, 34). Funding to support transfusion services, 
especially the hospital-based model, is scarce, since traditionally, the use of replacement 
donors has been discouraged. Funders may even tie their funds to conditions such as the 
exclusive use of voluntary, non-remunerated donors (4), even though donations from the 
replacement system provide a substantial proportion of the blood supply. Only 11 countries in 
Sub-Saharan Africa, for example, have managed to achieve 100% of blood donations from 
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voluntary, non-remunerated donors, and overall, only 67% of donations come from voluntary 
non-remunerated donors (3, 35). Globally, 83.3% of donations are voluntary, non-
remunerated donations, 16.4% are family or replacement donations, and 0.3% are paid 
donations (3). There are efforts, however, to increase numbers of voluntary, non-remunerated 
blood donations, particularly among adults with the lowest risk profiles (Box 1).  
 
Box 1. Improving repeat, voluntary, non-remunerated blood donation in LMICs: “Pledge 25” clubs 
Pledge 25 clubs—sometimes called post-school donor clubs—are an Africa-wide initiative supported by the 
Africa Society for Blood Transfusion and the Global Blood Fund that started in Zimbabwe in 1994 (36). It 
targets young adults and members pledge to donate 25 units of blood before the age of 30. Members also make 
a commitment to adhering to a healthy, low-risk lifestyle (37). These clubs seek to create the safest donor profile 
possible, and have been successful across various contexts. For example, in Zimbabwe in 2010, almost 26% of 
blood donors throughout the country—which is one of the few in Africa to maintain a 100% voluntary, non-
remunerated volunteer base—were from Pledge 25 clubs (36). 
 
 
Low availability of blood donors and inadequate cold chain maintenance and pathogen 
testing also contributes to low blood stocks (29). Stockouts of blood may occur in both 
hospitals and central blood banks, regardless of the donation model used. For example, in 
Uganda, an audit of large hospitals providing critical care found that only 66% of requests for 
transfusions were fulfilled. Among the 34% who did not receive the transfusion required, for 
two thirds of them, the hospital blood bank ran out of blood, and for the remaining third, the 
national blood bank did not have enough blood (38). Innovative technologies are being used 
in some high-income countries to maintain adequate blood stocks (Box 2). 
 
Box 2. Using an innovative technology to encourage blood donation in the UK’s National Health 
Service 
In the UK, an estimated 200,000 new donors are needed each year. To underline the life-saving capacity of 
blood transfusions and its importance in healthcare, the National Health Service in the UK launched a new 
campaign. A large billboard is in front of a group of people, who have been given stickers on their arms where 
a needle might go if they were donating blood. Using a smartphone app, they can watch as their arm gets a 
needle and some tape and their blood starts to flow. On the billboard, they can see directly their blood filling a 
bag for a recipient. The impact of the transfusion is clear, as the ill recipient gets better and better before their 
eyes. The recipients used in the campaign are not just actors, they are people who have been saved through 
blood transfusions. The campaign has not yet been evaluated, but is anticipated to prompt an increase in blood 
donation (39).  
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SCREENING BLOOD 
The high population prevalence of infections and weak infrastructure for screening and 
documentation, means that transfusion-transmitted infections are of concern in LMICs (3). In 
Sub-Saharan Africa, 1.3% of blood units were estimated to be reactive to HIV, 4.2% to 
Hepatitis B virus, 1.0% for Hepatitis C virus, and 0.8% for syphilis (3, 35). Here, pregnant 
women and children under the age of five are at the greatest risk of acquiring such infections, 
as they are the largest recipients of blood donations (29). 
 
The use of rapid tests has been promoted, especially in LMICs, but they have variable 
sensitivity and need to be validated to the settings in which they are to be used (40, 41). 
Ideally, tests for the most common transfusion-transmittable infections, such as HIV, 
Hepatitis B virus, and Hepatitis C virus, should be highly sensitive to reduce the risk of 
transmitting infection to blood recipients (42). Nucleic acid testing provides maximum 
sensitivity, but is prohibitively expensive for LMICs (29), so efforts to improve the 
sensitivity and use of rapid diagnostic tests are important (41). There are some promising 
examples of such innovation emerging (Box 3).  
Box 3. Use of compact microfluidics technology to test for transfusion-transmittable infections 
Despite the preference for centralised blood banking models, in many LMICs, out of necessity, hospital-based 
collection and testing of blood persist. Low cost, durable, sensitive tests are therefore needed to ensure the 
highest safety of blood possible, given many restraining factors. A portable, point-of care system is being 
introduced by an American company called Daktari Diagnostics. This system uses microfluidic devices that 
require only a small amount of blood. Tests for HIV and Hepatitis C virus can be performed at the same time, 
capturing key cellular indicators and counting the virus, giving an estimate of viral load within 30 minutes.  
 
Microfluidic devices are low-cost, have low power consumption, and have fast sampling and processing. A 
sensitive, cost-effective test may prove a reasonable substitute for less effective rapid tests in many LMICs (43).  
  
 
Stockouts of testing kits for transfusion-transmittable infections are common in LMICs, 
having been  reported by 20 countries in Africa, and 15 other countries across all regions 
except Europe (3). Globally,13 countries (six in Africa, three in the Americas, three in the 
Western Pacific, and one in the Eastern Mediterranean) have reported being unable to test for 
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one or more of the four key transfusion-transmittable infections: HIV, Hepatitis B virus, 
Hepatitis C virus, and syphilis. Globally, HIV testing rates for blood for transfusion range 
from 91.5% to 99.7%, Hepatitis B virus testing from 26.8% to 98.5%, Hepatitis C virus from 
17.5% to 99%, and syphilis from 66% to 98.4% (3).  
 
GETTING BLOOD TO WOMEN WHO NEED IT, WHEN THEY NEED IT 
In many settings, especially those with large rural populations and a high prevalence of home 
births, a significant barrier exists in terms of getting women to facilities, and eventually, to a 
facility that has the capacity to provide a blood transfusion. Referral systems linking to 
higher-level facilities are often inadequate or absent (44). Helping women in LMICs 
adequately prepare for birth during pregnancy by identifying a blood donor, identifying a 
facility give birth in, and arranging resources for transportation, are critical for preventing 
delays and achieving better outcomes for women with PPH (45). Community sensitisation 
and mobilisation can be helpful in terms of helping to get women who need blood to facilities 
where transfusions are available (Box 4).  
 
Box 4. Mobilising communities for increased uptake of skilled attendance at birth 
Options, a UK-based non-governmental organisation, worked from 2015–2018 on a “Maternal and 
Newborn Improvement” programme, with the central aim of increasing skilled attendance at birth. At 
the conclusion of the intervention period, skilled birth attendance increased from 41% to 84%. There 
were a number of activities that were carried out to achieve this result. One was the retraining of 
traditional birth attendants as birth companions, who could confirm a woman was in labour and be 
with her on her way to the hospital and throughout labour and childbirth. Another was the provision 
of vouchers that could be used to subsidise the cost of motorcycle transport—the most common 
method of transportation, especially in rural settings. One-third of women arriving at facilities for 
birth had done so using these vouchers. A third area of intervention was around the introduction of a 
performance-based financing scheme in health facilities to improve the quality of care. Finally, 
facilities were also equipped with solar power, to prevent blackouts (46).  
 
 
Rapid transfer of blood to remote facilities, rather than transferring women to higher-level 
facilities, has also gained momentum recently through the use of drones (Box 5).  
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Box 5. Use of drones for the transport of blood 
Drones may have the capacity to deliver blood over long distances. A study by Amukele and colleagues found 
that blood samples flown for three hours (258 km) in a cooling box, experienced only minor differences in 
glucose and potassium levels, suggesting the overall feasibility of drone transport of blood, albeit with stringent 
environmental controls (47). 
 
The Ministry of Health in Rwanda has capitalised on drone technology to reduce deaths due to PPH. Staff in 
three district hospitals—located in remote, mountainous areas that are difficult to reach via road—can use their 
phones to order blood by drones. In Rwanda, a centralised blood banking system exists, but barriers in getting 
blood to peripheral facilities have been largely overcome through drone technology (48).  
 
DOCUMENTATION OF PATIENT DATA 
Patient documentation in higher-income settings is generally robust, and often electronic. 
However, the use of electronic health records is far from ubiquitous, and in many LMIC 
health systems, inconsistently applied or unavailable (49), with severe implications for blood 
transfusion.  
 
In LMICs, there may be additional barriers to the correct documentation of patient data. For 
example, some patients may have inconsistent spelling of their name, they may not know 
their birthdates, and most records are hand-written. Staff may therefore struggle to identify 
the correct blood transfusion recipient and to administer the blood due to lack of training. 
Systems for monitoring and documentation of vital signs and adverse events during and after 
transfusion are scarce in LMICs. This puts women with PPH at particular risk, since for them, 
transfusions are often administered in an acute emergency, and correct documentation is  
critically important to prevent unnecessary transfusion-related complications and deaths (4). 
Innovations to improve the documentation of patient information, including details critical for 
blood transfusions, are increasingly available (Box 6).  
 
Box 6. Mobile storage of personal health information 
Mobile technologies are increasing rapidly worldwide, including in LMICs. In Benin, prompted by the 
unnecessary death of a patient during childbirth who could not remember her blood type—and for whom such 
information was not documented—Dr. Vena Ahouansou created a technology company that uses tech to store 
and transfer medical information. People use their mobile phones to register for an application that logs key 
personal medical information, including blood type. The company then places the information into a QR code 
that can be made into a bracelet ($4 USD), or added as a patch on a mobile phone or other personal item ($2 
USD). Once the patch or the bracelet is scanned by users of the application, the necessary medical information 
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of that person appears (50). Such technology could be coopted by blood transfusion services for providers to 
both store and access critical patient information. 
 
 
DECIDING WHEN TO PERFORM A BLOOD TRANSFUSION FOR POSTPARTUM 
HAEMORRHAGE 
Before the correct treatment can be given, it is essential that a prompt and accurate diagnosis 
of PPH can be made (44). Often, particularly in LMICs, providers estimate blood loss 
visually, which can underestimate postpartum blood loss by 33–50% (6). Gold standards like 
the use of photospectometry and estimation of blood loss through calibrated bags are much 
more accurate, and while common in high-income settings, are little-used in LMICs. In these 
settings, clinicians have to rely on monitoring of the patient’s vital signs, blood test results, 
and timely diagnosis of the cause of haemorrhage to determine the best course of action to 
minimise morbidity and mortality (6). There are emerging opportunities, however, to better 
diagnose the severity of PPH to determine if a blood transfusion is required (Box 7). 
Box 7. Bedside fibrinogen testing to determine the severity of PPH and need for transfusion 
Due to problems surrounding accurate diagnosis of PPH in LMICs, other markers have been suggested as 
reliable indicators of severe PPH. For example, clotting factors like fibrinogen decrease rapidly, early on in 
PPH, exacerbating bleeding. Judging the speed of the fall of fibrinogen may be an important marker of severity, 
and can be assessed with a bedside test (12). A bedside test—ROTEM—highlighted the possibility of assigning 
cut-off values, based on ROTEM parameters, to determine a transfusion threshold value, thus minimising the 
unnecessary use of transfusions for PPH management (51). What remains is research into lower-cost diagnostic 
devices, like ROTEM, for application in LMICs.  
 
 
REDUCING THE NEED FOR BLOOD TRANSFUSIONS  
While blood transfusions can and do save lives, ensuring that blood transfusions are used 
only when absolutely necessary is important for a number of reasons. Firstly, blood 
transfusions can be dangerous and should only be used as a last resort. The estimated in-
hospital case fatality rate following blood transfusions across health facilities in Africa is 6–
20% (21). Secondly, blood transfusions are expensive. For example, in Sub-Saharan Africa, 
the cost per unit of blood transfused can be more than 80 USD for a unit of whole blood, and 
95 USD for red cell concentrates (52). These values are found within the context of an 
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average expenditure per capita on health of 30 USD in LMICs (53). Unnecessary blood 
transfusions can result in considerable wasted resources. For example, in Mexico, 47.8% of 
blood transfusions carried out in one hospital between 1 January and 30 June 2015 did not 
have adequate clinical indication, costing the hospital an estimated $861,000 USD per year 
(54). For obstetric bleeding, uterotonics like oxytocin, ergometrine, and misoprostol, 
especially in combination, can stop haemorrhage and may be more cost-effective than 
providing a blood transfusion (55). An alternative to allogenic blood transfusions is the use of 
autologous transfusions—using the recipient’s own blood—which have been suggested by 
some authors for possible treatment of PPH. Autologous blood transfusions have been used 
safely in obstetrics, particularly for treatment of ectopic pregnancies. This approach is 
possible, even in low- and middle-income countries. For example, in Benin, over 200 
procedures of autologous blood transfusion for treatment of ectopic pregnancy were carried 
out, using a Tanguieta funnel. This perforated funnel is placed inside the peritoneal cavity, 
where it collects blood. The blood is filtered and aspirated into prepared transfusion bags, 
where it can be reinfused into the patient. A similar approach of retrieval, filtering, and 
reinfusion may be possible for the management of postpartum haemorrhage (25). However, 
there are limited data around this approach, and a need for more research. An additional 
approach, specifically for women at risk of haemorrhage who undergo a caesarean section, is 
intraoperative cell salvage (Box 8).  
 
Box 8. The use of intraoperative cell salvage during caesarean section when women are at high risk of 
haemorrhage 
 
During a caesarean section, blood is lost. To minimise the use of donated blood—which is a finite resource—
between June 2013 and April 2016, Khan and colleagues worked across 26 UK obstetric units, carrying out 
intraoperative cell salvage for women at risk of haemorrhage undergoing caesarean section amongst a 1498 
women as part of a randomised controlled trial. The control group had 1492 women, who received routine care. 
The rate of transfusion was slightly lower (2.5% compared to 3.5% in the control group) for the intervention 
group undergoing cell salvage (OR 0.65, p = 0.056), with the strongest effect for emergency caesarean sections 
(OR 0.58, 95% CI 0.34 to 0.99). Fetomaternal haemorrhage was higher in the intervention group when the 
woman was rhesus-D negative and the baby was rhesus-D positive (OR 5.63, 95% CI 1.43 to 22.14), 
highlighting the need for adherence to anti-D prophylaxis protocols to minimise risk. Overall, there was modest 
evidence of the applicability of cell salvage to minimise the use of allogenic blood transfusion (56). More 
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research into the applicability of this approach, particularly in low- and middle-income countries where 
allogenic blood transfusion may not be an option, or itself carries life-threatening risks, would be valuable. 
 
TREATMENT OF ANAEMIA 
There is a close relationship between anaemia, PPH, and severe maternal outcomes, so the 
prevention, early diagnosis, and treatment of anaemia and its causes can reduce unnecessary 
blood transfusions (57). In LMICs, anaemia diagnosis is often based solely on clinical 
symptoms, leading in some instances to the inappropriate use of blood transfusion. In 
addition to exposing the patient to unnecessary risks, this may not be a cost-effective 
approach since a haemoglobin test is around 40 times cheaper than a unit of blood (29). 
Mobile technologies are emerging as a possible solution to the sensitive diagnosis of anaemia 
(Box 9). 
 
Box 9. Use of smartphone technology for rapid, sensitive anaemia testing 
In the case of PPH, screening for anaemia is important. New technology that can be used to rapidly 
and accurately test a woman’s blood for anaemia, has been introduced. Using a smartphone-based 
imaging cytometry platform, the density of red and white blood cells and haemoglobin concentration 
can be captured. A separate optical attachment to the phone takes the image, which is then processed 
immediately on a phone application, giving a rapid analysis, on par with a much more expensive 
benchtop haematology analyser. Results can be stored on the phone or sent to a central server, where 
they can be utilised to provide remote diagnosis if a skilled technical person is not on-hand (58). 
 
 
Interventions like supplementation of iron and folic acid during antenatal care, malaria 
prevention and treatment in malaria-endemic areas and treatment of helminth infection in 
helminth-endemic areas can substantially reduce anaemia, and are cost-effective and 
relatively easy to implement (59, 60). An example from paediatric care indicates that, barring 
instances of congestive heart failure, giving children iron treatment, as opposed to transfusion 
for iron-deficiency anaemia, offers better recovery (61). 
 
QUALITY ASSURANCE AND HAEMOVIGILANCE 
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In 155 (87%) countries, including 44 (96%) from Africa, there are specific standards around 
the collection, testing, processing, storage, and distribution of blood and blood components 
(3). However, in LMICs, there are a myriad of barriers preventing implementation of these 
standards (62). Therefore, low-cost interventions like quality improvement, which can aid the 
implementation of pre-existing standards of care around all aspects of blood transfusion, may 
be beneficial, particularly in such contexts (Box 10). 
 
Box 10. Standards-based audit to improve the quality of blood transfusion services 
Standards-based audit (sometimes called “clinical audit” or “criterion-based audit”) is a problem-solving 
approach frequently applied in clinical settings to improve the quality of care (63). Standards around blood 
transfusion are widespread, particularly in Africa (3). Applying standards-based audit, facility-based audit teams 
select a standard of care that they are not meeting (for example, routine screening of all blood donations for 
HIV, Hepatitis B and C, and syphilis). They collect some data to understand the extent of the problem, and then 
design and implement solutions to address the problem. After a period of implementation, a second 
measurement to determine progress will be carried out. Teams can work on as many standards of care as they 
are able to. Over time, the cumulative impact of this quality improvement approach can be marked (64). Quality 
improvement that relies on local solutions to local problems, is felt to be particularly appropriate for LMICs, 
where resource constraints are pronounced (65). 
 
 
In high-income countries, 99.6% of donations were screened, following quality assurance 
processes, compared to 97% in upper-middle income countries, 81% in lower-middle income 
countries, and 66% in low-income countries. In LMICs, hospitals play an important role in 
transfusion services, owing to an absence of robust, centralised blood banking and 
distribution systems (32). However hospitals may have an underdeveloped transfusion 
infrastructure and lack transfusion policies, monitoring and evaluation systems, named 
persons responsible for the oversight of the quality of blood transfusions, and robust 
documentation processes (66). 
 
Haemovigilance is the monitoring and evaluation of any adverse events that are due to blood 
transfusion. These findings are very important in the continual improvement of blood 
transfusion services. However, only 39% of countries globally reported having such a system 
in place, including 77% of countries in Europe, and only 14% of countries in the Americas.  
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FINANCING BLOOD SERVICES 
Investment in blood transfusion services in low-resources settings is often insufficient to 
establish and sustain safe and adequate national blood supplies (3). In Sub-Saharan Africa, 
78% of countries reported reliance on external, and therefore likely unsustainable, support. 
For example, between 2011–2014, PEPFAR gave $437 million USD to 14 countries across 
Sub-Saharan Africa and the Caribbean. While this funding contributed to an increase in blood 
collections by 19%, without this funding, these gains may recede (21). Only 16% of countries 
reported any kind of cost recovery, which is the model used to finance 67% of blood 
transfusion services in Europe (3). 
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PRACTICE POINTS 
• Preventing and managing anaemia in pregnant women should be prioritised to reduce 
the risks of poor outcomes from PPH and to minimise the use of blood or blood 
components.  
• Women should be encouraged to give birth with a skilled attendant present, who 
should be trained to recognise severe anaemia as a risk factor for PPH. 
• Effective active management of the third stage of labour, the use of uterotonics, 
uterine massage, and other methods should be used to the greatest extent possible to 
manage PPH. Blood transfusion should be used as a last resort. 
 
 
 
RESEARCH AGENDA 
• Implementation research around strategies to reduce the number of women entering 
third stage of labour with significant anaemia   
• Better methods of diagnosing PPH and high-risk women in LMICs to avoid 
unnecessary blood transfusions, and to ensure that blood transfusions do occur when 
needed 
• Further research around alternatives to allogenic blood transfusion, such as 
autologous blood transfusions, or intraoperative cell salvage, particularly in resource-
constrained settings 
• Ongoing research into low-cost, high-sensitivity blood tests to reduce the risks of 
transfusion-transmitted infections 
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• Overall health policy and systems research to promote health systems strengthening, 
particularly around establishment of referral infrastructure and financing for 
transfusion services.  
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SUMMARY 
There are many barriers, and some innovative solutions, to the provision of timely, quality blood 
transfusions for the management of PPH. The challenges are particularly pronounced in LMICs, 
where the highest prevalence of both anaemia and PPH are found. The need for innovation to 
increase repeat, voluntary donation from low-risk donors, including converting replacement 
donors into regular donors, are critically important. Centralised models of blood banking, while 
desirable, may be unaffordable and impractical in LMICs. There are exciting new technologies 
that could improve the sensitivity of point-of-use testing, such as the use of mobile technologies 
or microfluidic chips, and of linking patient information to transfusions using mobile 
technologies. Blood may be provided faster to women with PPH through ensuring better referral 
processes, adequate supplies at health facilities, and transportation of blood and blood 
components to remote regions using drones. Improving the way that PPH is diagnosed, to fully 
understand if and when blood transfusions are necessary, may help to eliminate risky, costly 
blood transfusions. Technologies like bedside fibrinogen tests may assist in assessing the 
severity of PPH, and the need for blood transfusions. Alternatives to allogenic blood transfusion, 
such as autologous blood transfusion or intraoperative cell salvage, may also be life-saving 
options, particularly where there are barriers around the timely provision of blood transfusion. 
Finally, improving the effectiveness and safety of blood transfusions through hospital-based 
quality improvement activities has great potential to enact the standards of care for blood 
transfusions for PPH that exist across LMICs, but that are poorly implemented. Overall, health 
systems strengthening and context-sensitive cost-recovery financing mechanisms for blood 
transfusion services are essential for the sustainability of high quality blood services that will 
benefit all those needing transfusions, including women with PPH.  
